Ocular Therapeutix (0OT) Price & Analysis
0OT Stock Chart & Stats
- Day’s Range
- EUR 6.35 - EUR 6.40
- 52-Week Range
- EUR 5.55 - EUR 13.66
- Previous Close
- EUR 6.55
- Volume
- 0
- Average Volume (3M)
- 250
- Market Cap
- EUR 1.37B
- Enterprise Value
- EUR 1.69B
- Total Cash (Recent Filing)
- EUR 598.64M
- Total Debt (Recent Filing)
- EUR 79.38M
- Price to Earnings (P/E)
- ―
- Beta
- 0.56
- Next Earnings
- Nov 09, 2026
- EPS Estimate
- -0.32
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins
Consistently high gross margins indicate that Ocular Therapeutix’s products and technology can generate substantial value after direct costs. This provides a solid economic foundation for future scale, although operating discipline and sufficient revenue growth are still needed to convert gross profit into sustainable earnings.
Manageable Leverage
Improved leverage and a sizable asset and equity base provide greater financial flexibility than the company had in earlier periods. This can support continued development and commercialization efforts, while reducing balance-sheet pressure as management works to improve profitability and cash generation.
Specialized Ophthalmic Platform
A focused ophthalmic platform built around bioresorbable hydrogel delivery gives Ocular Therapeutix a differentiated basis for developing therapies that improve dosing convenience and clinical outcomes. This specialization can support product expansion and strategic relevance across multiple eye-disease indications.
Bears Say
Worsening Operating Losses
Worsening operating losses show that the company is not yet converting its strong gross margins into sustainable earnings. Continued losses can constrain investment choices, increase dependence on external financing, and make it harder to fund pipeline development without shareholder dilution.
Persistent Cash Burn
Persistent negative operating and free cash flow means the business currently lacks self-funding capacity. If cash outflows remain elevated, Ocular Therapeutix may need additional financing to sustain development and commercialization, increasing funding risk and potentially limiting strategic flexibility.
Leadership Continuity Risk
The departure of the executive responsible for shaping long-term strategy creates a leadership continuity risk during an important development and commercialization phase. A replacement or transition process may affect strategic execution, corporate planning, and confidence in management consistency over the coming quarters.
Ocular Therapeutix News
0OT FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
What is Ocular Therapeutix’s market cap?
When is Ocular Therapeutix’s upcoming earnings report date?
How were Ocular Therapeutix’s earnings last quarter?
Is Ocular Therapeutix overvalued?
Does Ocular Therapeutix pay dividends?
What is Ocular Therapeutix’s EPS estimate?
How many shares outstanding does Ocular Therapeutix have?
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ocular Therapeutix?
What is the TipRanks Smart Score and how is it calculated?
Ocular Therapeutix Stock Smart Score
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pravin U. Dugel
- Employees
- 325
- Website
- www.ocutx.com
- Address
- 24 Crosby Drive, Bedford, MA, 01730, US
Ocular Therapeutix (0OT) Earnings & Revenues
0OT Earnings Call
Earnings Call SentimentPositive
The call conveyed a strongly positive clinical narrative: a landmark superiority result (p=0.0006), clear durability and anatomic benefits, an encouraging safety profile, robust enrollment and accelerated timelines for SOL-R, initiation of a long-term extension (SOL-X), and a solid cash position. The primary negatives were regulatory/timing uncertainty, the explicit note that cash runway excludes full commercialization costs, and limited disclosure of some granular metrics. On balance, the highlights substantially outweigh the lowlights.
View all DE:0OT earnings summaries0OT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |